The presence of cis-configured exchangeable ligands has long been considered a
prerequisite for antitumor activity of platinum complexes, but over the past few years, several …

Mechanistic studies are presented of a novel class of aminophosphine platinum (II)
complexes as potential anticancer agents. These new agents, which have demonstrated …

The global modification of mammalian and plasmid DNAs by novel platinum compounds,
trans-[PtCl2 (NH3)(Am)], where Am= 2-methylbutylamine or sec-butylamine was …

The global modification of mammalian and plasmid DNAs by novel platinum compounds, cis-
or trans-[PtCl2 (NH3)(Am)], where Am= NH3, nonplanar heterocycle piperidine, piperazine …

Replacement of the ammine group in antitumor cisplatin by a heterocyclic ligand (piperidine,
piperazine, or 4-picoline) results in reduction of cytotoxicity in human ovarian cancer cells …

The requirement for novel platinum antitumor drugs led to the synthesis of dinuclear
bisplatinum complexes. To understand the molecular mechanisms underlying the biological …

cis-[Amminedichloro (2-methylpyridine)] platinum (II)(AMD473) is a novel sterically hindered
anti-tumour compound designed to circumvent platinum drug resistance and is due to begin …

Recent findings that novel trans-dichloroplatinum (II) complexes exhibit antitumor activity
violate the classical structure-activity relationships of platinum (II) complexes. These novel …

As part of a drug discovery program to discover more effective platinum-based anticancer
drugs, a series of platinum complexes of trans coordination geometry centered on trans …

A paradigm for the structure-pharmacological activity relationship of bifunctional platinum
antitumor drugs is that the trans isomer of antitumor cisplatin (transplatin) is clinically …